Prlnl ed in U. '.A ,
Some drugs have pharmacologic effects when they interact with li ght. Certa in low-molecularweight, nuorescing chemicals of tricyclic structure absorb ultraviolet or visible light, providing energy for photochemical reactions. Nuclear, cytoplasmic. and cell membrane alterations can be induced in living cells; increasing doses of drug or light can cause death of bacteria, viruses, one-celled organisms, and tissue culture cells. Systemic or topical administration of t hese chemicals and subsequent exposure to the proper waveband of light can lead to e rythema of normal human skin.
Photochemotherapy defines the combination of light and drug to bring about a beneficial effect. Usually, in the doses used , neither the drug alone nor the light alone has any significant biologic activity; it is only the combination of drug and light which is therapeutic . PUV A (psoralen and UV-A) is a term used to describe oral administration of psoralen and sub equent exposure to UV-A (long-wave ultraviolet light, 320-400 nm l.
Certain fu rocoumarins. called psoralens. are t ricyclic structures which may be con idered derivatives of coumarin (Fig. 1) . Although psoralens can be synthesized by adding a furan ring on a suitably sub tituted coumarin derivat.ive, the most photoactive psoralens are found in nature in plants and microorganisms. Although the major absorption spectrum for psoralen lies bet.ween 210 and 330 nm. the action spectrum for photo ensitization and photochem ical changes is within wavelengths longer than :120 nm, In the presence of long-wave ultraviolet radiation (320-4oo nm. UV -A) these ,ubstances induce a reversible cutaneous photosensitivity manifested by what appears as an augmented sunburn reaction and subsequent hype rpigmentation [11 . The two psoralens commercially avai lable in the United States. methoxsalen (B-methoxypsoralen. 8-MOP) and t rimethylpsora len (4,5 '.B-trimethylpsoralen. TMP) are very potent photoactive drugs causing redness of normal human skin in }lg/cm' quantities applied topi cally if the skin is subsequently exposed to It has been shown that B-MOP and subsequen t UV-A exposure leads to inhi bition of DNA synthesis 12-41. Photoexcited psoralen molecules transfe r the absorbed ultraviolet energy to D A. Psoralen covalently binds to DNA forming monofunctional photoadducts with thymine bases and bifunctional interstrand cross-links between oppos ite pyrimidine base pairs 15-7). Topical psoralens and UV-A exposure leads to regression of psoriatic plaques [8] [9] [10] .
This report summarizes the cutaneous effects of oral administration of 0.6 mg/ kg of 8-MOP and subsequent exposu re to UV-A. This drug-ligh t corn bination causes erythema and pigmentation of normal skin and has beneficial effects on psoriasis.
The PUVA erythema reaction can be severe and is the limiting factor during treatment. While psoriasis treatment courses may require 10 to 20 PUV A treatments. redness and pigmentation occur after a single PUV A exposure if doses of dru g and light are adequate . The occurrence and degree of redness. however. is related to dose of both drug and light and is predictable. The erythema which results from PUVA differs from sunburn in its time course. PUVA redness may be absen t or just beginning at 12 to 24 hr after ult raviolet exposure (when UV-B or sunburn erythema is normally at its peak), and may peak at 4 to 72 hr or later. Since skin diseases can be treated at drug-l ight exposure doses which are less than the doses causing evere redness. careful dosimetry permits relatively safe PUVA treatments.
The pigmentation which results from PUVA appears histologically and morphologically to be similar to normal melanogenesis (delayed tanning). Pigmentation maxim izes about 5 to 7 days after PUVA exposu re and lasts weeks to months. A patient's genetic ability to tan (facultative tanning ) dictates the degree and limits of delayed pigmentation. Baseline melanization (constitutive tanning ) along with sunburn history, number of previous sun or PUVA exposu res, and thickness of skin influence the amou nt of UV -A energy needed to penetrate into t.he skin to cause photobiologic reactions. In general, one or t wo erythemogenic PUVA exposures ca n stimulate melanogenesis t.o the same degree as can multiple UV-B or su n exposures.
Redness, pigmentation, and therapeutic responses to PUVA depend on (1) 
than this may cause nausea and light-headedness in some patients. The pre irradiation period is 2 hr because the drug is maximally susceptible to photoactivation at that time (Fig. 2) . It is important to note that the skin remains photosensitive to UV-A for 6 to 8 hr after ingestion. If prolonged sun exposure occurs, persons a re at risk of exaggerated erythema from solar UV-A during the 6-to 8-hr period after ingestion.
The dose of UV -A is given in joules/cm', a joule being 10 ' ergs. When speaking of energy dose one should also specify the unit of area and specify which wavelengths, frequency, or photon energy are being used. An example of a dose used to begin therapy in a Caucasian is 3.5 joules/ em' of UV-A (320-400 nm 1. Initial UV -A exposure doses in Caucasians actually vary from 1.0 to 5.0 joules/ cm', depending on melanization and sunburn history. Exposure doses must be increased as tanning occurs.
The ideal light source is one which has highintensity UV-A and om its most or all of wavelengths below 320 nm. High-intensity UV-A is needed to make treatment times shorter and more practical for the patient. Omission of the shorter, more erythemogenic wavelengths avoids the discomfort and confusion of superimposing a sunburn rea ction on the PUVA erythema reacti on. Wavelengths shorter than 320 nm are as much as 1000 times more efficient at causing erythema of normal Caucasian skin than is UV-A. Orall y administered F,G . !. Psoralen. psoralens, in the dosage used for methoxsalen photochemotherapy, reduce this difference in erythemogenic potential to about 100-fold. The shorter wavelengths remain much more erythe· mogeni c despite large doses of psoralens.
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To insure patient comfort. excessive amounts of visib le light and infrared radiation must also be om itted . Ideal light systems must a lso be large enough to radiate all exposed skin surfaces at once. The intensity s hould be uniform at varying distance from the light source so that all exposed skin surfaces receive the same dose of ultraviolet light. Accurate and reliable means of metering and delivering doses of light should be built into the treatment system.
In initial studies performed in Boston [11 J and in Vienna 112J and in subsequent treatment of over 300 additional patients (unpublished data l. repeated PUVA exposures (8 to 24) caused complete clearing of psoriasis in over 90 % of patients. Another 8% of patients were more than 95 '* improved, and 2% of patients were not significantly improved. In 54 bilateral compa'rison studies, PUVA was seen to be supe ri or to conventional UV-B phototherapy. Maintenance therapy kept 85o/c of patients free of psoriasis for up to 400 days [12J.
Severe pruritus and mark ed redness in localized areas were seen often during the early phases of oral p oralen photochem otherapy but became less severe and less frequent as more experience was gained and dosimetry became more exact. In treatment of the last 100 patients. therapy has nol been interrupted because of itching or redness. although in 2% of patients both were a problem. No abnormalities in alkaline phosphatase, serum glutamic oxaloacetic transaminase. com plet e blood cou nt, urinalysis. hilirubin, or blood urea nitrogen which could be attributed to photochemotherapy were noted in any patient.
Beca use the effects are limited to the skin ir radiated by UV.A, PUVA combines the ease of administration of oral medication with the safety of topical medication. However, scalp and body folds do not respond if light does not reach those areas. The scalp of bald patients or persons with short haircuts responds well. Patients do not have to be hospitalized for therapy. Infrequent treatments are required (2 to 3 times per week) and it appears that weekly maintenance keeps most patients free of psoriasis for months . While the acute limiting factor of the P UV A reaction is erythema, this can be avoided by careful dosime· try.
Large doses of 8-MOP and long exposures 10 high-intensi ty UV -A causes skin cancer and cat~ racts in laboratory animals. These. effects have not been seen in man in over 20 years of use of methol(salen and UV -A for treatment of vitili go. These side effects may not be produced in humans in the dose of drug and light used or they may be ,0 infrequent that they have not come to the atten· tion of the clinician. Careful observation and prospective studies are needed. It may also be that repeated phototoxic reactions over many years may lead to actinic cha nges in t he skin, especially skin which pigments poorly or not at all. On the other hand, patients who tan well may actually be protected by PUV A; the striking melanogenesis, by acting as a sunscreen, may permit less cumula tive sola r-induced changes over many decades. The physician must weigh the theoretical risks a nd the psychological stress of psoriasis against the benefits of effective photochemotherapy.
